Progression study

What is SNAP?

It will represent the first fruits of the SERA project. It will study 200 patients from the SERA cohort, and do in-depth analysis of cytokines, chemokines, RNA, DNA and analytical FACS. These will be compared to clinical outcomes such as: clinical remission; rapid radiographic progression; and drug toxicity.

How is the study being funded?

SNAP is an exciting collaboration between SCAR and Pfizer, who are providing funding of >£3 million

When will it run?

SNAP is expected to be completed by 2012